GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kiniksa Pharmaceuticals Ltd (NAS:KNSA) » Definitions » Price-to-Owner-Earnings
中文

Kiniksa Pharmaceuticals (Kiniksa Pharmaceuticals) Price-to-Owner-Earnings

: (As of Today)
View and export this data going back to 2018. Start your Free Trial

As of today (2024-04-23), Kiniksa Pharmaceuticals's share price is $17.78. Kiniksa Pharmaceuticals does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Kiniksa Pharmaceuticals's Price-to-Owner-Earnings or its related term are showing as below:

During the past 8 years, the highest Price-to-Owner-Earnings of Kiniksa Pharmaceuticals was 7.90. The lowest was 3.95. And the median was 6.20.


KNSA's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 32.26
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-04-23), Kiniksa Pharmaceuticals's share price is $17.78. Kiniksa Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.18. Therefore, Kiniksa Pharmaceuticals's PE Ratio for today is 98.78.

As of today (2024-04-23), Kiniksa Pharmaceuticals's share price is $17.78. Kiniksa Pharmaceuticals's EPS without NRI for the trailing twelve months (TTM) ended in was $0.18. Therefore, Kiniksa Pharmaceuticals's PE Ratio without NRI for today is 98.78.

During the past 8 years, Kiniksa Pharmaceuticals's highest PE Ratio without NRI was 120.78. The lowest was 3.87. And the median was 5.61.


Kiniksa Pharmaceuticals Price-to-Owner-Earnings Historical Data

The historical data trend for Kiniksa Pharmaceuticals's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kiniksa Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial - - - 6.83 -

Kiniksa Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.83 3.97 5.19 - -

Competitive Comparison

For the Biotechnology subindustry, Kiniksa Pharmaceuticals's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kiniksa Pharmaceuticals Price-to-Owner-Earnings Distribution

For the Biotechnology industry and Healthcare sector, Kiniksa Pharmaceuticals's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Kiniksa Pharmaceuticals's Price-to-Owner-Earnings falls into.



Kiniksa Pharmaceuticals Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Kiniksa Pharmaceuticals's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=17.78/-0.29
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kiniksa Pharmaceuticals  (NAS:KNSA) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Kiniksa Pharmaceuticals Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Kiniksa Pharmaceuticals's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Kiniksa Pharmaceuticals (Kiniksa Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
2 Church Street, Clarendon House, Hamilton, BMU, HM11
Kiniksa Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; Vixarelimab; and KPL-404.
Executives
Michael R Megna officer: Chief Accounting Officer 1050 HINGHAM STREET, ROCKLAND MA 02370
John Paolini officer: Chief Medical Officer C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Barry D Quart director C/O INTRABIOTICS PHARMACEUTICALS INC, 1009 OAK HILL ROAD, SUITE 201, LAFAYETTE CA 94549
Felix Baker director BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors Lp director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Baker Brothers Life Sciences Lp director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
L.p. 667, director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors (gp) Llc director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Julian Baker director BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Eben Tessari officer: Chief Business Officer C/O KINIKSA PHARMACEUTICALS LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Arian Pano officer: Chief Clinical Dev. Officer C/O KINIKSA PHARMACEUTICALS LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Ross Moat officer: Group VP & Rilonacept GM C/O KINIKSA PHARMACEUTICALS LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Sanj K Patel director, 10 percent owner, officer: Chairman & CEO C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Thomas W. Beetham 10 percent owner, officer: Chief Legal Officer C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Mark Ragosa officer: Interim CFO C/O KINIKSA PHARMACEUTICALS CORP., 100 HAYDEN AVENUE, LEXINGTON MA 02421